Breaking News on Contract Research, Manufacturing & Clinical Trials

Hot Topics > Consolidation

Consolidation

The pharmaceutical industry seems besieged on all sides by declining R&D productivity, expiring patents and relentless downward pricing pressure. One effect of this onslaught has been an upsurge in the level of consolidation as industry players attempt to cut costs, expand research pipelines and lengthen geographic reach.

BREAKING NEWS

Biogen Idec selects Quintiles in 5-year strategic partnership

24-Apr-2014 - Biogen Idec’s five-year deal is the latest example of biopharma embracing the strategic partnership model, but the choice of Quintiles is somewhat of a surprise, according to ISI analyst Ross...

CROs to profit from large slice of $91bn biotech pie, say analysts

10-Apr-2014 - Much of the $91bn (€66bn) raised in biotech capital over the last twelve months will end up in the hands of the CRO industry, according to a survey from analyst...

Pernix leaves CMO business behind, sells off last manufacturing facility in Texas

03-Apr-2014 - Pernix Therapeutics will no longer be a CMO as it has signed a definitive agreement to divest its Houston, Texas-based manufacturing operations to Woodfield Pharmaceutical to cut costs.

Completed Galapagos deal to boost 2014 sales by $70m for Charles River

02-Apr-2014 - Argenta and BioFocus will add approximately $70m (€51m) to Charles River Laboratories’ 2014 revenues, the firm and an analyst say.

Dispatches from interphex

Consolidation prevalent in industry, says third largest CMO

26-Mar-2014 - Aenova says the acquisition of Haupt Pharma and Patheon’s merger with DSM are evidence of consolidation in the CMO industry, as it looks to further increase its global footprint.

Evotec buys academic asset management specialist

24-Mar-2014 - Evotec AG has bought an asset management company that specialises in bringing academic discovery and development innovations to the attention of pharma and biopharma sponsors.

DISPATCHES FROM INTERPHEX

Patheon and DSM crossover limited, more growth targeted says DPx

20-Mar-2014 - Patheon and DSM’s Pharma Products merger is “highly complementary” with crossover limited to North American oral solid manufacturing growth, says DPx as it targets further growth opportunities.

Patheon and DSM fully complementary for biologics post-merger, says DPx Exec

14-Mar-2014 - Patheon brings fill/finish capabilities to DSM’s biomanufacturing services, President of Biopharma at the recently merged company DPx told Biopharma-Reporter.com in an exclusive interview.

Exclusive interview

CMO future? Consolidation and strategic alliances, says Patheon/DSM Exec

13-Mar-2014 - In an exclusive interview, Patheon Executive Mike Lehmann talks DSM integration, further growth and how consolidation amongst CMOs may be driving strategic alliances with pharma.

breaking news - update 2

CRL to buy Argenta and Biofocus from Galapagos for €134m

13-Mar-2014 - Preclinical CRO Charles River Labs has announced plans to buy discovery services firms Argenta and BioFocus from Galapagos NV.

Exclusive interview

INC Research expands into Middle East with MEK acquisition

10-Mar-2014 - In a sign of further consolidation, CRO INC Research has acquired CRO MEK Consulting and will absorb its more than 40 employees based in the Middle East and north Africa.

DSM's pharma biz reports slight growth before Patheon merger

26-Feb-2014 - DSM has reported modest growth in its pharma business as a shareholders advisory firm comes out in favour of the upcoming merger with Patheon.

Private equity firm buys Medpace for $915m, citing growth opportunities

24-Feb-2014 - CRO consolidation has left market opportunities for providers who serve mid-size pharma, UK-based private equity firm Cinven says as it acquires Medpace.

Icon: FY13 bolstered by M&A strategy, bolt-on acqusitions to continue

24-Feb-2014 - Icon says it intends to continue its M&A strategy focusing on capabilities, geographies and technologies as it reports a robust 2013.

Pharma consolidation a boon to CROs, but only the larger ones, report says

19-Feb-2014 - Mid-tier pharma mergers and a shift to more complex trials will benefit broad-based CROs, whilst smaller outsourcing partners will be forced to consolidate, an industry report by Citi Research predicts.

CRL to close MI research model unit, as preclinical biz blossoms

12-Feb-2014 - Charles River Laboratories says it will shutter a Research Models and Services (RMS) facility in Michigan as softened demand for the sector offset a strong year for its preclinical service...

CTI Trial, Clinical Consulting acquire Community Research

03-Feb-2014 - CROs CTI Trial and Clinical Consulting recently acquired Community Research, David Blume, managing director of Edgemont Capital, told us.

Catalent looks to go public with $100m IPO

30-Jan-2014 - Catalent has filed an initial public offering (IPO) with the SEC to raise $100m though this could reach upwards of $500m, according to one investment firm.

News in brief

GVK Bio to move into US with Aragen Purchase

30-Jan-2014 - Asia’s leading small-molecule CRO GVK BIO will acquire the capital stock of US-based CRO Aragen Bioscience. 

CRL looks to strategic alliances to drive growth across changing clientbase

20-Jan-2014 - Strategic relationships with both big pharma and mid-tier firms will drive future growth, says Charles River laboratories (CRL).

McKesson's strategy unclear after $8.3bn Celsio takeover falls through

14-Jan-2014 - Whether McKesson will relaunch its bid to acquire German logistics firm Celsio has been questioned by analysts after the proposed $8.3bn (€6.1bn) takeover bid fell through.

Merck Millipore sells its discovery and development service biz to Eurofins

09-Jan-2014 - Merck Millipore has sold its Discovery and Development Solutions (DDS) Business to Eurofins saying it was unable to fully support.

Patheon third largest CMO and top PDS provider, report says as DSM merger looms

08-Jan-2014 - Patheon is the world’s largest pharmaceutical development services (PDS) provider and third largest contract manufacturer, according to a report released yesterday.

Cyprotex buys CeeTox to expand preclinical services biz

02-Jan-2014 - Cyprotex has bought CeeTox in a bid to diversify its revenue base beyond its core pharmaceutical preclinical services business.

Chiltern consolidates ownership after Kester Capital sells stake

19-Dec-2013 - A private equity investor has sold its stake in CRO Chiltern leading to a restructured ownership the firm says will encourage expansion.

Key Industry Events

 

Access all events listing

Our events, Events from partners...